In this paper we report a review of the results obtained in the last few years by our group in the development of ruthenium (Ill) 
Introduction
Despite the leading role played by cis-dichlorodiammineplatinum(II) (hereafter called cisplatin) and by other platinum complexes in anticancer chemotherapy, the number of neoplasms that can be succesfully treated with these compounds is still limited. Platinum derivatives are in fact scarcely active against several malignancies with high social incidence, such as non-small cell lung carcinomas, lung adenocarcinomas and adenocarcinomas of the colon and rectum [1] [2] [3] [4] . As a consequence, there is a considerable interest in investigating compounds of other transition metals as potential antineoplastic agents [5] [6] [7] [8] . The aim of this reasearch is that of finding new active Vol. 1, No. 1, 1993 Water-Soluble Ruthenium(IIl)-Dimethyl Sulfoxide Complexes [9, 10] , Sn [11] [12] [13] , Rh [14] , Au [15] , Ti [16] [17] [18] [19] and Ru. In this paper we will focus on ruthenium derivatives.
The antiturnor properties of simple chloro-arnmino-ruthenium(III) derivatives were first investigated by M.J. Clarke [20] [21] [22] [23] [24] [25] . Two complexes of this class, namely cis-[Ru(NH3)4C12]C1 and/hc-Ru(NH3)3C13 (Figure 1 ), showed a significant activity against P388 leukemia, reaching T/C values of 154 and 189, respectively. In more recent years Keppler and coworkers reported that anionic Ru(III) complexes with eterocyclic nitrogen ligands (L) of general formula (LH)2[RuC15L] [26] and (LH)[trans-RuC14L2] [27] have good antitumor activity against several screening tumor lines [28] [29] [30] [31] . H In this tumor model, whose sensitivity to chemotherapeutic agents is virtually the same as that of its human counterpart, the ruthenium derivatives resulted considerably more active in reducing the tumor mass than the clinically used drug, 5-fluorouracil. No hypothesis was advanced on the mechanism of action of such complexes, which are now in advanced preclinical stage [31] . An "activation by reduction" mechanism was instead proposed [20] [21] [22] [23] [24] [25] to explain the activity of the chloro-ammino ruthenium derivatives that are considerably inert toward ligand loss opening up coordination positions. According to this hypothesis the inert, and therefore inactive, Ru(lll) complexes are considered as prodrugs that can be activated by an in situ reduction to the corresponding more labile Ru(II) species. These should be able to form covalent bonds with biological targets after relatively rapid dissociation of some ligands. A biologically accessible redox potential is obviously required for a complex in order to fit in such mechanism. A higher Ru(ll)/Ru(IIl) ratio might be expected in solid tumor tissues, that are generally considered as reducing, hypoxie environments compared to surrounding, more aerated tissues [32, 33] . This [24, 25, 31, 35] . Ru(llI) has indeed a high affinity for the transferrin Fe-binding sites, and the protein might play an important role in the cellular uptake mechanism of ruthenium [31, 34, 35] . In such hypothesis, an accumulation of ruthenium in tumor masses might be expected, owing to the high iron requirement of rapidly growing tumor tissues that involves a large number of transferrin receptors.
Our group has been investigating the biological properties of ruthenium-sulfoxide complexes since the late seventies. Dimethylsulfoxide (DMSO), like the other sulfoxides of general formula R1R2SO, is an ambidentate ligand (Figure 2 ), as it can coordinate to a metal center either through the sulfur atom (DMAO) or through the oxygen atom (DMS O) [36, 37] . [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] , and more recently focused on Ru(IlI) derivatives [49] [50] [51] [52] [53] [54] [55] [56] . In this paper we will report a survey of our latest results of ruthenium(llI)-sulfoxide complexes from three different, but strictly related, points of view: structure and chemical behavior, antitumor activity and interactions with DNA, considered as one of the possible molecular targets.
Results and Discussion
Chemical Aspects. The precursors of the compounds subject of this study are (DMSO)2H[trans-RuC14(DMSO)2] (1) and its sodium salt and mer-RuC13(DMSO) 3 (2) . The synthetic pathways to 1 and 2 and their structural features [51] are schematically reported in Figure 3 . A completely analogous scheme might be drawn for the corresponding tetramethylenesulfoxide (TMSO) derivatives 3 and 4 [49] . The ruthenium(llI)-sulfoxide complexes 1-4, being structurally very similar to the Ru(III) compounds with heterocyclic nitrogen donor ligands reported by Keppler [26, 27] , aptared particularly attractive in the perspective of finding new derivatives to be tested for antitumor activity. In fact, the anionic compounds are isostructural and isoelectronic to ICR, with S-bonded sulfoxides replacing the nitrogen ligands. Unlike ICR, however, the ruthenium-sulfoxide complexes proved to be rather labile in aqueous solution, in particular at physiological pH where they are readily hydrolized [51 ] .
Although complexes 1-4 resulted scarcely attractive for pharmacological development due to their lability, the investigation of their reactivity led us to observe that one of the two trans S-bonded sulfoxides could be easily substituted by a nitrogen ligand [55] .
According According to the measured El/2, a biological reduction process is thermodynamically possible for all the derivatives [24] . In this respect it is interesting to compare the El/2 value of 5 with that of ICR, which we found to be -0.511 V under the same conditions. This last value sits at the lower limit of the biologically accessible potentials suggesting that, in the hypothesis of an "activation by reduction" mechanism operating in dvo for these Ru(llI) complexes, the sulfoxide derivatives might be expected to behave quite differently from ICR despite their structural similarity. Due to their greater solubility in water, anionic complexes of class A are more attractive for being developed as drugs. Accordingly, most of the pharmacological and chemical investigations to date have been focused on this class of compounds. The chemical behavior of the anionic complexes has been studied both in unbuffered distilled water and in phosphate-buffered solutions at physiological pH. The stability of the complexes in the slightly acidic distilled water can give valuable informations concerning the administration of the product, while the behavior under physiological conditions is strictly related to the mechanism of action of the complexes and their in 4vo distribution. a) Distilled water. The evolution with time of the complexes has been followed by 
The case of the N-methylimidazole derivative is particularly significative to this regard and is reported in Figure 6 . Upon chloride dissociation, the broad resonance of DMAO moves from -15 ppm to approx -11 ppm, while the sharper resonance of N-CH 3 moves from -1 ppm to + 1 ppm. Only one signal for the imidazole protons could be detected (it moves from-3.8 pprn to-0.5 ppm during step 1), the others being very likely too broad to be detected. Only a small amount of free DMSO (6%) could be found at the end of step 1. The reaction rate of this step increases along with the pH. We also found that, in the presence of catalytic amounts of reducing agents, the reaction rate remarkably increases and the kinetic profile becomes of pseudo-first order ( Figure  7 ). These data suggest that chloride substitution is catalyzed by traces of Ru(II) species; similar processes have already been described for inert Ru(lll) species [20] . In the absence of added reductants, we hypothize that an autoreduction process, parallel to the substitution reaction, is the source of Ru(ll) species. A partial reduction due to trace impurities in solution would not explain the autocatalytic pattern, since in that case the amount of catalyst would be constant since the beginning. The presence of traces of added biological reductants promotes the formation of an equivalent amount of catalyst, so that the reaction proceeds mainly through the catalyzed path and becomes zero order in the catalyst and first order in the reactant.
In the second step of the reaction the product that built up in step 1 is transformed into a new species. This process involves the decrease of the absorption maximum at approx 346 nm, with formation of a new maximum at higher frequencies (325 nm) and a concomitant gradual increase of the background absorption (Figure 8 ). An isosbestic point is still maintained. Step 2 is independent on the concentration of OH-and, unlike step 1, its rate is not influenced by the presence of trace reductants. However, stoichiometric amounts of reductants introduced in solution at this stage determine complete reduction to Ru(ll) species.
In agreement with the blue-shift observed in the visible spectrum, step 2 has been tentatively attributed to the dissociation of a further chloride but, according to the NMR spectra, it is also accompanied by the partial dissociation of DMSO and of the nitrogen ligand. However, since no new signals for bound ligands appear in the NMR pattern during this step, formation of a dimeric species might be also hypothized. In this hypothesis the presence of two paramagnetic centers would broaden the signals of coordinated ligands to such an extent as to make them undetectable. 21. From these studies it is evident how, independently on the compound being used, the effects on lung metastasis formation are always higher than those on primary tumor growth. Interestingly, Na[trans-RuC14(TMSO)Iq] that, given the significant cytotoxicity for tumor cells evidenced in dtro against TLX5 lymphoma cells (Table 3) , was expected to give the higher reduction of primary tumor growth, resulted instead endowed with a rather weak activity against tumor growth and lung metastases; similarly it resulted scarcely active on TLX5 lymphoma or on P388 leukemia, including the cisplatin resistant subline, after in dvo treatments (Table 4) Anyhow, it must be stressed that, although the activity on tumors of lymphoproliferative type such as the P388 lymphocytic leukemia are not much impressive (Table 4) , all compounds tested were active on the cisplatin resistant line, in some cases with an activity clearer than that observed on the parental line, thus indicating that rutheniumdimethylsulfoxide complexes do not exibit cross resistance with cisplatin itself. [60] , but probably also because on spontaneous lung metastases it can overcome the problems of chemosensitivity usually found within tumor cells of primary tumors, which can also be present on artificial metastases. This behaviour can be explained taking into account the differences in growth kinetics between spontaneous and artificially induced lung metastases, where the latter have been described to show marked similarities with the primary tumor from G. Mestroni 
Metal Based Drugs which they arose [61, 62] . Therefore with guanine sequences with G > 2 [48 ] .
From the compared examination of data of Table 6 and of the effects on experimental (Table 4) and a similar lack of activity against TLX5 lymphorna in 4tro ( (Table 7) . The high propensity to reduce the growth of lung metastases is evidenced also when treatment occurs after surgical ablation of primary tumor, that is on an advanced stage of growth of the metastatic tumor. In this condition, a treatment schedule can be found that significantly prolongs the life-span of the tumor-bearing animals with an efficacy that is in agreement with the effects of reduction of lung involvement by the metastatic tumor (Table 8) .
Again, as shown previously, Na[trans-RuC14(TMSO)Iq] is scarcely active after in t4vo treatment also on host's survival time (Table 7) . 
